Broad screening of inflammation-associated proteins identifies serum CCL19 as a novel biomarker of disease activity in IgG4-related disease
Annals of the Rheumatic Diseases · 2026-11 · 85 (11) · 2253-2262
DOI: 10.1016/j.ard.2026.03.015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of the Rheumatic Diseases, 2026-11. Verfasst von Federica Bonaso und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Immunology, and Inflammation, Massachusetts General Brigham, Boston, MA, USA; Center for Immunology and Inflammatory Diseas…. Hauptthemen laut MEDLINE: Immunoglobulin G4-Related Disease, Chemokine CCL19. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: National Institute of Allergy and Infectious Diseases Division of Intramural Research, National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases.
Abstract (Originalsprache)
OBJECTIVES: IgG4-related disease (IgG4-RD) is a chronic immune-mediated disease characterised by mass-forming lesions. The smouldering tempo and often asymptomatic nature of IgG4-RD pose challenges in the monitoring of disease activity. The goal of this study is to identify novel biomarkers capable of distinguishing active disease from remission. METHODS: Ninety-two inflammation-associated proteins were measured across 67 patients with IgG4-RD, 49 healthy donors (HDs), and 21 patients with sarcoidosis. Statistical analyses were adjusted for age, sex, race, and false discovery rate. Biomarkers that distinguished IgG4-RD were studied by unsupervised hierarchical clustering, receiver operator characteristic curves, and statistical analyses. Quantitative enzyme-linked immunosorbent assay (ELISA) was used to validate findings in a cohort of 80 patients with IgG4-RD, including 28 patients with paired longitudinal samples, and 80 age, sex, and race-matched HDs. RESULTS: Twelve inflammation-associated proteins distinguished IgG4-RD. Although most markers correlated with one another, CCL19, CCL2, and CCL13 were the most distinguishing of IgG4-RD. Among these, only CCL19 decreased during treatment-induced remission relative to active IgG4-RD. CCL19 correlated with clinical and laboratory parameters of disease activity and severity. Quantitative ELISA validated the systemic elevation of CCL19 in patients with IgG4-RD. CCL19 performed similarly to IgG4 in dynamically declining in response to treatment and increasing with subsequent relapse. Importantly, CCL19 and IgG4 supplemented one another in distinguishing active disease from remission. CONCLUSIONS: CCL19 is a novel and promising biomarker for the longitudinal monitoring of disease activity in patients with IgG4-RD and may provide supplemental value to IgG4 in identifying relapsing disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, Immunology, and Inflammation, Massachusetts General Brigham, Boston, MA, USA; Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA, USA; Allergy Unit, ASS…
- Division of Rheumatology, Immunology, and Inflammation, Massachusetts General Brigham, Boston, MA, USA.
- Division of Rheumatology, Immunology, and Inflammation, Massachusetts General Brigham, Boston, MA, USA; Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical S…
- Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA, USA.
- Harvard Medical School, Boston, MA, USA; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
- Division of Pulmonary & Critical Care Medicine, Massachusetts General Hospital, Boston, MA, USA.
Förderung
- National Institute of Allergy and Infectious Diseases Division of Intramural Research
- National Institutes of Health
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
Zitieren
APA
Bonaso, F., Jiang, B., Yockey, L. J., Akaa, J., Doyle, I., Hsu, E., LeSon, C., McMahon, G., Jha, I., Montesi, S. B., Katz, G., Guy, T. V., Mahajan, V. S., Pillai, S., Lee, P., Stone, J. H., Wallace, Z. S., & Perugino, C. A. (2026). Broad screening of inflammation-associated proteins identifies serum CCL19 as a novel biomarker of disease activity in IgG4-related disease. Annals of the Rheumatic Diseases, 85(11), 2253-2262. https://doi.org/10.1016/j.ard.2026.03.015
Vancouver
Bonaso F, Jiang B, Yockey LJ, Akaa J, Doyle I, Hsu E, et al. Broad screening of inflammation-associated proteins identifies serum CCL19 as a novel biomarker of disease activity in IgG4-related disease. Annals of the Rheumatic Diseases. 2026;85(11):2253-2262. doi:10.1016/j.ard.2026.03.015
BibTeX
@article{Bonaso2026,
author = {Bonaso, Federica and Jiang, Bohang and Yockey, Laura J and Akaa, Jesse and Doyle, Ian and Hsu, Evan and LeSon, Courtney and McMahon, Grace and Jha, Isha and Montesi, Sydney B and Katz, Guy and Guy, Thomas V and Mahajan, Vinay S and Pillai, Shiv and Lee, Pui and Stone, John H and Wallace, Zachary S and Perugino, Cory A},
title = {Broad screening of inflammation-associated proteins identifies serum CCL19 as a novel biomarker of disease activity in IgG4-related disease},
journal = {Annals of the Rheumatic Diseases},
year = {2026},
volume = {85},
number = {11},
pages = {2253--2262},
doi = {10.1016/j.ard.2026.03.015}
}
EUVIMED